Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon β-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis

NCT01158183 COMPLETED

A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.

Details

Lead sponsor	Bayer
Status	COMPLETED
Enrolment	226
Start date	2007-07
Completion	2009-09

Conditions

• Multiple Sclerosis, Relapsing-Remitting

Interventions

• BAY86-5046_Interferon-beta-1b

Primary outcomes

• Key Objective: To collect patient reported outcomes and clinical assessments via the same web-based data capture tool in a real world setting in relapse-remitting multiple sclerosis patients — Baseline, 1 to12 month outcome questionnaires

Countries

United States